Literature DB >> 19002883

A new complementing cell line for replication-incompetent E1-deleted adenovirus propagation.

Qingfu Xu1, Maria T Arevalo, Michael E Pichichero, Mingtao Zeng.   

Abstract

Recombinant adenoviruses (Ad) are being explored as promising delivery systems for gene therapy and vaccination. However, there is a concern about the possibility of generating replication-competent adenoviruses (RCA) using the human embryonic kidney 293 cell line. We have constructed a new cell line named the UR cell line which can be used to produce Ad vectors free of RCA. This cell line is based on the human embryonic lung HEL 299 cell. We first constructed a shuttle plasmid which encodes the E1A/E1B sequence that is necessary for adenovirus replication. The shuttle plasmid was then transfected into HEL 299 cells. The presence of the E1A/E1B sequence and protein expression in the stably transformed UR cells was confirmed. Viruses produced in UR cells were still RCA-free after ten test passages, while adenovirus produced in 293 cells had generated RCA during the fourth passage. We conclude that the UR cell line is sufficiently stable, can effectively produce a virus yield comparable with 293 cells, and does not generate RCA formation during Ad propagation.

Entities:  

Year:  2006        PMID: 19002883      PMCID: PMC3449810          DOI: 10.1007/s10616-006-9023-6

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  21 in total

1.  Guidance for human somatic cell therapy and gene therapy.

Authors: 
Journal:  Hum Gene Ther       Date:  2001-02-10       Impact factor: 5.695

Review 2.  Production of first generation adenovirus vectors: a review.

Authors:  X Danthinne; M J Imperiale
Journal:  Gene Ther       Date:  2000-10       Impact factor: 5.250

3.  AdEasy system made easier by selecting the viral backbone plasmid preceding homologous recombination.

Authors:  M Zeng; S K Smith; F Siegel; Z Shi; K R Van Kampen; C A Elmets; D C Tang
Journal:  Biotechniques       Date:  2001-08       Impact factor: 1.993

4.  Development of a packaging cell line for propagation of replication-deficient adenovirus vector.

Authors:  J S Kim; S H Lee; Y S Cho; K Park; Y H Kim; J H Lee
Journal:  Exp Mol Med       Date:  2001-09-30       Impact factor: 8.718

Review 5.  Biology of adenovirus and its use as a vector for gene therapy.

Authors:  Michael J McConnell; Michael J Imperiale
Journal:  Hum Gene Ther       Date:  2004-11       Impact factor: 5.695

Review 6.  Recombinant adenoviruses as vaccines.

Authors:  V Randrianarison-Jewtoukoff; M Perricaudet
Journal:  Biologicals       Date:  1995-06       Impact factor: 1.856

7.  A simplified system for generating recombinant adenoviruses.

Authors:  T C He; S Zhou; L T da Costa; J Yu; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

8.  Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy.

Authors:  N Mittereder; K L March; B C Trapnell
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

9.  Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence.

Authors:  K M Hehir; D Armentano; L M Cardoza; T L Choquette; P B Berthelette; G A White; L A Couture; M B Everton; J Keegan; J M Martin; D A Pratt; M P Smith; A E Smith; S C Wadsworth
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

10.  Characterization of replication-competent adenovirus isolates from large-scale production of a recombinant adenoviral vector.

Authors:  J Zhu; M Grace; J Casale; A T Chang; M L Musco; R Bordens; R Greenberg; E Schaefer; S R Indelicato
Journal:  Hum Gene Ther       Date:  1999-01-01       Impact factor: 5.695

View more
  4 in total

1.  Protective immunity against tularemia provided by an adenovirus-vectored vaccine expressing Tul4 of Francisella tularensis.

Authors:  Ravinder Kaur; Shan Chen; Maria T Arévalo; Qingfu Xu; Yanping Chen; Mingtao Zeng
Journal:  Clin Vaccine Immunol       Date:  2012-01-25

2.  Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine.

Authors:  Mingtao Zeng; Qingfu Xu; Md Elias; Michael E Pichichero; Lance L Simpson; Leonard A Smith
Journal:  Vaccine       Date:  2007-09-05       Impact factor: 3.641

3.  Adenoviral producer cells.

Authors:  Imre Kovesdi; Susan J Hedley
Journal:  Viruses       Date:  2010-08-16       Impact factor: 5.818

4.  An adenoviral vector-based mucosal vaccine is effective in protection against botulism.

Authors:  Q Xu; M E Pichichero; L L Simpson; Md Elias; L A Smith; M Zeng
Journal:  Gene Ther       Date:  2009-01-08       Impact factor: 5.250

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.